


**Claims:**

1. A combination for simultaneous, separate or sequential use which comprises (a) a nitrogen mustard analogue selected from chlorambucil, chlornaphazine, estramustine, mechlorethamine, mechlorethamine oxide hydrochloride, navembichin, phenestrine, prednimustine, trofosfamide and uracil mustard and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide having the following formula



in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt.

2. The combination according to claim 1 which is a fixed combined pharmaceutical composition.
3. The combination according to claim 1 or 2 wherein (a) and (b) are present in synergistically effective amounts.
4. The combination according to claim 1, 2 or 3 wherein the nitrogen mustard analogue is chlorambucil.
5. Use of a combination according to any one of the preceding claims for the treatment of chronic lymphocytic leukemia.
6. Use of a combination according to any one of the preceding claims for the preparation of a medicament for the treatment of chronic lymphocytic leukemia.

- 17 -

7. The use according to claim 5 wherein leukemia is a chlorambucil-resistant chronic lymphocytic leukemia.
8. A method of treating a warm-blooded animal having chronic lymphocytic leukemia comprising administering to said animal a combination according any one of claims 1 or 2 in a quantity which is jointly therapeutically effective against said disease and in which the compounds can also be present in the form of their pharmaceutically acceptable salts.
9. The method according to claim 8 wherein (a) chlorambucil is administered at a dose of 0.2 to 0.8 mg/kg of body weight/day and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide is administered at a dose of 50 mg to 800 mg per day.
10. A pharmaceutical composition comprising a quantity, which is jointly therapeutically effective against chronic lymphocytic leukemia of the combination according to claim 1 or 2 and at least one pharmaceutically acceptable carrier.
11. A commercial package comprising a pharmaceutical composition according to claim 10 together with instructions for simultaneous, separate or sequential use thereof in the treatment of chronic lymphocytic leukemia.
12. Use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide in free form or in the form of a pharmaceutically acceptable salt for the manufacture of a medicament for use in combination with a nitrogen mustard analog selected from chlorambucil, chlornaphazine, estramustine, mechlorethamine, mechlorethamine oxide hydrochloride, navembichin, phenestrine, prednimustine, trofosfamide and uracil mustard for use in the treatment of chronic lymphocytic leukemia.
13. The use according to claim 12 wherein the nitrogen mustard analogue is chlorambucil.